HealthRX.com · Printable lab tracker
NAD+ blood test timing record for NMN or NR
NAD+ results depend on what was measured and when the blood was drawn relative to your last dose. Note both every time, so one test can be compared with the next. The timing facts come from the two human studies charted on this page.
What the two timing studies measured
- After a 1,000 mg NR dose, blood NR peaked at about 3 hours in half of 8 volunteers; the other half showed no clear change.[1]
- Where a clear peak was seen, blood NR fell with a half-life of about 2.7 hours.[1]
- At steady state, average whole-blood NAD+ was 100% above baseline, but individual rises ranged from 35% to 168%.[1]
- Safety blood tests in that study were drawn after a 6-hour fast and before that day's NR dose.[1]
- The 60-day NMN trial measured total NAD+ plus NADH in serum, and compared each group with its own baseline and with placebo at day 30 and day 60.[2]
Your product and routine
Product name and formNMN or NR; capsule, powder or sublingual
Amount per serving and servings per day
Usual time of your doseand whether you take it with food
Date you started this amount
Test-by-test record
Use the test name and units exactly as the lab report prints them.
| Date and clock time of draw | Hours since last dose | Fasting? (hours) | Test name and sample type | Result and units | Lab and reference range |
|---|---|---|---|---|---|
Questions for the lab or your clinician
- Is this whole blood, serum, plasma or a blood-cell measurement?
- Does the result count NAD+ alone, or NAD+ and NADH together?
- Should my next sample be drawn at the same time after my dose, and fasting, so the two are comparable?
- How much change between two results is within this test's normal variation?
- Would a result change what we do, or is it for interest only?
Sources for the facts on this sheet
- Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One 2017. PMID 29211728. https://pubmed.ncbi.nlm.nih.gov/29211728/
- Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience 2023. PMID 36482258. https://pubmed.ncbi.nlm.nih.gov/36482258/
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.